New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
08:30 EDTCRIS, RHHBYCuris licenses worldwide development, commercialization rights for IAP Inhibitor
Curis (CRIS) announced that it has licensed from Genentech, a member of the Roche Group, (RHHBY), exclusive, worldwide rights for the development and commercialization of GDC-0917, a small molecule that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins. Genentech has recently completed a Phase I clinical trial of GDC-0917, in which 42 people received daily oral doses of GDC-0917 for two weeks, followed by a one week rest period. This 21-day cycle is repeated until disease progression or study discontinuation for any other reason. The primary endpoints of the study include evaluating the safety and tolerability and the pharmacokinetics of GDC-0917 in people with solid tumors or lymphoma and determining the maximum-tolerated-dose and a potential recommended dose for further clinical studies. Secondary endpoints include a preliminary assessment of anti-tumor activity of GDC-0917 and evaluating pharmacodynamic markers. Genentech plans to present full study results at a medical conference in mid-2013, Curis said.
News For CRIS;RHHBY From The Last 14 Days
Check below for free stories on CRIS;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
07:30 EDTRHHBYQ1 Productions to hold a conference
Subscribe for More Information
July 25, 2014
07:35 EDTRHHBYEMA recommends new indication for RoActemra in severe arthritis
Subscribe for More Information
July 24, 2014
06:13 EDTRHHBYRoche reaffirms outlook for 2014
Subscribe for More Information
06:12 EDTRHHBYRoche reports 1H core EPS CHF 7.57 vs. CHF 7.58 last year
Subscribe for More Information
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information
July 14, 2014
11:20 EDTRHHBYExelixis seen as potential target for Roche, TheStreet says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use